RE-BVS – Piemonte Repository

Sfoglia per AUTORE
FRIGENI M
Collezione AOU Novara

Items : 3

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts. in American journal of hematology / Am J Hematol. 2023 Aug;98(8):E204-E208. doi: 10.1002/ajh.26960. Epub 2023 May 24.

2023
AOU Alessandria
ASL Città di Torino
ASL Torino 4
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Della Porta MG; Santini V; Naldi I; Finelli C; Sancetta R; Selleri C; Pasini P; Giordano L; Turrini M; Tosi P; Tanasi I; Frigeni M; Grimaldi D; Marchetti M; Norata M; Galimberti S; Fianchi L; Di Veroli A; Ferrara F; Di Bona E; Bono R; Castelli A; Calvisi A; Rivoli G; Molteni A; Nicolino B; Occhini U; Leuzzi L; Genua A; et alii...

Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. in Leukemia / Leukemia. 2020 May;34(5):1462-1466. doi: 10.1038/s41375-019-0687-2. Epub 2019 Dec 13.

2020
AOU Novara

Frigeni M; Besson C; Visco C; Fontaine H; Goldaniga M; Visentini M; Pulsoni A; Torres HA; Peveling-Oberhag J; Rossotti R; Zaja F; Rigacci L; Merli M; Dorival C; Alric C; Piazza F; Gentile M; Ferrari A; Pirisi M; Nassi L; Rattotti S; Frustaci A; Milella M; Cencini E; Defrancesco I; Ferretti VV; Bruno R; Hermine O; Arcaini L; et alii...

Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas. in The oncologist / Oncologist. 2019 Aug;24(8):e720-e729. doi: 10.1634/theoncologist.2018-0331. Epub 2018 Dec 14.

2019
AOU Novara

Merli M; Frigeni M; Alric L; Visco C; Besson C; Mannelli L; Di Rocco A; Ferrari A; Farina L; Pirisi M; Piazza F; Loustaud-Ratti V; Arcari A; Marino D; Sica A; Goldaniga M; Rusconi C; Gentile M; Cencini E; Benanti F; Rumi MG; Ferretti VV; Grossi P; Gotti M; Sciarra R; Tisi MC; Cano I; Zuccaro V; Passamonti F; et alii...